patisiran sodium

patisiran sodium (ONPATTRO) is an FDA-listed pharmaceutical active ingredient. Associated with Alnylam Netherlands B.V.. Route of administration: intravenous. Current US regulatory status: approved.

ONPATTRO is a marketed brand name for patisiran sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

patisiran sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.